Virtu KCG Holdings’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$1.4M Buy
35,565
+16,707
+89% +$610K 0.04% 387
2017
Q1
$591K Buy
18,858
+8,988
+91% +$281K 0.02% 1200
2016
Q4
$308K Sell
9,870
-15,021
-60% -$487K 0.01% 2062
2016
Q3
$1M Sell
24,891
-20,535
-45% -$773K 0.02% 703
2016
Q2
$1.51M Sell
45,426
-46,731
-51% -$1.6M 0.03% 486
2016
Q1
$2.71M Sell
92,157
-1,617
-2% -$44.6K 0.08% 174
2015
Q4
$2.47M Buy
+93,774
New +$2.44M 0.04% 326
2015
Q3
Sell
-37,392
Closed -$888K 3468
2015
Q2
$888K Sell
37,392
-69,654
-65% -$1.57M 0.02% 953
2015
Q1
$2.54M Sell
107,046
-40,314
-27% -$904K 0.05% 286
2014
Q4
$3.13M Buy
147,360
+74,580
+102% +$1.5M 0.05% 254
2014
Q3
$1.24M Buy
72,780
+3,042
+4% +$48K 0.02% 780
2014
Q2
$998K Sell
69,738
-71,268
-51% -$966K 0.02% 1178
2014
Q1
$1.74M Buy
+141,006
New +$1.63M 0.02% 785
2013
Q4
Sell
-63,786
Closed -$740K 3905
2013
Q3
$740K Buy
+63,786
New +$746K 0.01% 1519

Other funds holding EW

Virtu KCG Holdings's EW Position: Q2 2017 in Review

Virtu KCG Holdings increased its Edwards Lifesciences (EW) stake by 89% in Q2 2017, buying an estimated $610K and bringing the position to 35,565 shares worth $1.4M. The position accounts for 0.04% of the portfolio, ranked #387.

Virtu KCG Holdings first reported a position in EW in Q3 2013 and has held it in 14 quarters since. The position peaked at $3.13M in Q4 2014. 720 funds tracked by Wall St. Rank hold EW as of Q2 2017.

  • Virtu KCG Holdings held 35,565 shares of Edwards Lifesciences worth $1.4M as of Q2 2017.
  • Virtu KCG Holdings bought 16,707 Edwards Lifesciences shares in Q2 2017, an estimated $610K.
  • Edwards Lifesciences made up 0.04% of Virtu KCG Holdings's portfolio in Q2 2017, its #387 holding.
  • Virtu KCG Holdings first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 14 quarters since.
  • Virtu KCG Holdings's Edwards Lifesciences position peaked at $3.13M in Q4 2014.
  • 720 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.